Evidence map›Paper›PMID 35236966›Full record

ArticleOncogene2022

RNF4 silencing induces cell growth arrest and DNA damage by promoting nuclear targeting of p62 in hepatocellular carcinoma.

Bin Lv, Yida Pan, Daisen Hou, Ping Chen, Jun Zhang, Yiwei Chu, Mingqi Li, Yan Zeng, Dongqin Yang, Jie Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Regulation of apoptosis by ubiquitination in liver cancer.American journal of cancer research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bin Lv *Department of Digestive Diseases, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, China.
Yida Pan *Department of Digestive Diseases, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, China.ORCID http://orcid.org/0000-0002-1173-1074
Daisen HouInstitutes of Biomedical Sciences, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Shanghai, China.
Ping ChenInstitutes of Biomedical Sciences, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Shanghai, China.
Jun ZhangDepartment of Digestive Diseases, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, China.
Yiwei ChuDepartment of Immunology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Shanghai, China.
Mingqi LiCenter of Cancer Research, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Yan ZengCollege of Veterinary Medicine, Jilin Agricultural University, 2888 Xincheng Street, Changchun, China.
Dongqin YangDepartment of Digestive Diseases, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, China. kobesakura@fudan.edu.cn.ORCID http://orcid.org/0000-0003-0126-5898
Jie LiuDepartment of Digestive Diseases, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, China. jieliu@fudan.edu.cn.ORCID http://orcid.org/0000-0002-7638-187X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the largest causes of cancer-related deaths worldwide owing to the limitation of effective treatment options. The ubiquitin-proteasome system has been rapidly recognized as a frequent target of deregulation leading to cancers. Enhanced DNA damage response (DDR) promotes HCC growth and prevents chemosensitivity, and ubiquitin E3 ligases are key modulators in DDR. Therefore, a better understanding of how E3 ligases regulate cell growth and DNA damage may provide novel insights in understanding the oncogenic mechanism and improving the efficacy of DNA damage therapeutic agents. Here, we performed a high-content RNAi screening targeting 52 DDR-related E3 ligases in HCC and found that ring finger protein 4 (RNF4) was essential for HCC growth. RNF4 was highly expressed in HCC tissues, and the expression levels of RNF4 were associated with poor outcomes. RNF4 silencing significantly suppressed the cell growth, and subsequently induced G2/M arrest and apoptosis of HCC cells in vitro; RNF4 silencing also demonstrated the tumor-suppressive efficacy on HCC in vivo. Moreover, RNF4 silencing increased DNA damage, and rendered HCC cells more sensitive to DNA damage drugs and radiation. We found RNF4 functionally interacts with p62, and mechanistic analyses indicated that RNF4 silencing triggered the nuclear enrichment of p62. Moreover, the p62 nuclear targeting was required for increased DNA damage and growth suppression mediated by RNF4 silencing. Thus, our findings suggest RNF4 is essential for HCC proliferation via preventing nuclear translocation of p62. RNF4 silencing promotes DNA damage and may serve as a novel strategy to suppress cell growth and increase the sensitivity of DNA damage therapeutic agents in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNuclear ProteinsRNA-Binding ProteinsTranscription FactorsApoptosisCell Line, TumorCell ProliferationDNA DamageG2 Phase Cell Cycle CheckpointsHumansUbiquitinUbiquitin-Protein LigasesNuclear ProteinsP62 protein, humanRNA-Binding ProteinsRNF4 protein, humanTranscription FactorsUbiquitinUbiquitin-Protein Ligases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.